The investigators' preliminary study indicates that MSC is effective therapy in treating IBD. But the standard treatment is still lacking and the effect is not stable in IBD patients. This study is to explore the efficacy and standard strategy when using MSC in refractory IBD.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
3
The Drug including 6MP, AZA, infliximab and thalidomide
Injection of 3×10E6/kg of MSC
Injection of 6×10E6/kg of MSC
Clinical Response of CD patients 12 weeks after receiving treatment (Reduction of CDAI score at less 100)
Reduction of CDAI score at less 100
Time frame: 12 weeks after receiving treatment
Clinical Response of CD patients 6 weeks after receiving treatment (CDAI score less than 150)
CDAI score less than 150
Time frame: 6 weeks after receiving treatment
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Injection of NS